


BAY-826

Cat. No.:	HY-100756		
CAS No.:	1448316-08-2		
Molecular Formula:	C ₂₆ H ₁₉ F ₅ N ₆ OS		
Molecular Weight:	558.53		
Target:	Discoidin Domain Receptor; Tie		
Pathway:	Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (179.04 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
Preparing Stock Solutions	1 mM	1.7904 mL	8.9521 mL	17.9041 mL
	5 mM	0.3581 mL	1.7904 mL	3.5808 mL
	10 mM	0.1790 mL	0.8952 mL	1.7904 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1 mg/mL (1.79 mM); Clear solution			
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1 mg/mL (1.79 mM); Clear solution			
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1 mg/mL (1.79 mM); Clear solution			

BIOLOGICAL ACTIVITY

Description	BAY-826 is a selective and potent TIE-2 inhibitor with a K _d of 1.6 nM, respectively.
IC ₅₀ & Target	Tie2 1.6 nM (K _d)
In Vitro	BAY-826 is a selective and potent inhibitor of TIE-2 (dissociation constant = 1.6 nM) and binds with similar high affinity to only 4 of 456 tested kinases, namely, TIE-1, DDR1, DDR2, and Serine/threonine-protein kinase 10 (LOK) (dissociation

constant = 0.9, 0.4, 1.3, and 5.9 nM). The high biochemical affinity for TIE-2 translates into very potent cellular mechanistic activity with an EC₅₀ of about 1.3 nM for inhibition of TIE-2 autophosphorylation in human umbilical vein endothelial cells. The TIE-2 inhibitor BAY-826 is tested for its acute growth inhibitory as well as anti-clonogenic properties in all four mouse glioma cell lines. BAY-826 is highly selective against other angiogenic kinases, such as VEGFR, fibroblast growth factor receptor (FGFR), or Platelet-derived growth factor receptor (PDGFR), and affects VEGF-stimulated proliferation of HUVEC only at μ M concentrations, respectively.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BAY-826 (oral gavage; 25 mg/kg, 50 mg/kg, 100 mg/kg) potently inhibits ANG-1-stimulated TIE-2 autophosphorylation in murine lungs in female CB17/scid mice^[1].

BAY-826 improves tumor control in syngeneic mouse glioma models. Co-treatment with BAY-826 and irradiation is ineffective in one model (SMA-497), but provided synergistic prolongation of survival in another (SMA-560) cell. TIE-2 inhibition may improve tumor response to treatment in highly vascularized tumors such as glioblastoma^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay

Murine SMA-497, SMA-540, SMA-560, and GL-261 glioma cells are used. The cells are commonly cultured as adherent monolayers in Dulbecco's modified Eagle medium supplemented with 10% heat-inactivated fetal calf serum and 2 mM glutamine. Cells are irradiated in a Co-radiation source at 1, 3, and 9 Gy. The cells are pre-incubated for 10 min in the 37°C incubator either with 0.1% DMSO as control or 1 μ M BAY-826. TIE-2 autophosphorylation is induced for 20 min with either 4 mM Na₃VO₄ or with 400 ng/mL COMP-ANG-1 in the presence of either 0.1% DMSO or 1 μ M BAY-826^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration

Following anesthesia, a burr hole is drilled in the skull 2 mm lateral to the bregma. The needle of a Hamilton syringe is introduced to a depth of 3 mm. A volume of 2 μ L of a single cell suspension in PBS is slowly injected into the right striatum. In female and male VM/Dk mice (in-house husbandry) 5 \times 10³ SMA glioma cells are implanted, whereas in female C57Bl/6 mice (Charles River) 2 \times 10⁴ GL-261 cells are implanted (n = 10 per group). The mice employed have body weights > 20 g. Systemic treatment with BAY-826 is performed by oral gavage (100 mg/kg body weight daily) or the solvent (10% Ethanol/40% Solutol/50% Aqua dest), respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Schneider H, et al. J Neurochem. 2017 Jan; 140(1):170-182. doi: 10.1111/jnc.13877. Epub 2016 Dec 12. Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA